

Is it time to revise the normal range of serum uric acid levels?

G. DESIDERI¹, G. CASTALDO^{2,3}, A. LOMBARDI⁴, M. MUSSAP⁵, A. TESTA⁶,
R. PONTREMOLI⁷, L. PUNZI⁸, C. BORGHI⁹

¹Geriatric Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy

²Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy

³CEINGE-Advanced Biotechnologies, Naples, Italy

⁴General Practitioner, Florence, Italy

⁵Laboratory Medicine Unit, IRCCS AOU San Martino-IST, University-Hospital, Genoa, Italy

⁶General Practitioner, Castellamonte, Italy

⁷Department of Internal Medicine, University of Genoa and IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy

⁸Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy

⁹Internal Medicine Unit, Aging and Kidney Disease Department, University of Bologna, Bologna, Italy

Abstract. – The actual reference range of serum uric acid has been assessed according to its variations among healthy individuals. i.e. those without clinical evidence of gout. By this approach, serum uric acid values between 3.5 and 7.2 mg/dL in adult males and postmenopausal women and between 2.6 and 6.0 mg/dL in premenopausal women have been identified as normal in many countries. However, this definition of normal range of serum uric acid in the general population is inevitably influenced by what we consider as “normal”, since the absence of gout flares does not necessarily imply the absence of uric acid-related damage. Indeed, a growing body of evidence indicates that silent deposition of monosodium urate crystals as a result of hyperuricaemia may occur and lead to early destructive skeletal changes. In addition, a growing body of evidences demonstrates that uric acid might play a pathophysiological role in many “cardio-nephro-metabolic” disorders, which seems to be independent of the deposition of monosodium urate crystals, since it is evident also for serum uric acid concentrations below the saturation point for monosodium urate. Taken together, these findings strongly suggest to carefully reconsider the concept of “asymptomaticity” for chronic hyperuricemia and to consequently revise the normal range of serum uric acid levels also considering the progressive worldwide increase of circulating levels of uric acid, which could lead to a “shift to right” (i.e. toward higher values) of normal range. In the light of the new scientific knowledge on the pathophysiological role of uric acid in human disease, a threshold value < 6.0 mg/dL (< 360

µmol/L) seems to better identify true “healthy subjects” and should reasonably be considered for all subjects.

Key Words:

Uric acid, Hyperuricemia, Gout, Cardiovascular disease, Renal disease.

Introduction

The prevalence of hyperuricaemia and gout has been growing in Western countries for the last few decades^{1,2}. Gout is currently the most prevalent inflammatory arthritis in developed countries, especially in elderly men. Its prevalence is growing also in other parts of the world, such as New Zealand, where it reached 6.4% in 1992³, or Eastern China, where it reached 1.14% in 2008⁴. More recently a nationwide population-based study by Trifirò et al⁵ described an increase of the prevalence of gout in Italy from 0.7% in 2005 to 0.9% in 2009, with a male/female ratio of 4:1. A parallel trend towards an increasing prevalence of hyperuricaemia (serum uric acid > 6 mg/dL) was also observed (8.5% in 2005 vs 11.9% in 2009). However, the prevalence of hyperuricaemia in Italian people was lower than in other countries; indeed, epidemiological data showed an estimated prevalence of hyperuricaemia of 21% in the US general population⁶,

while population-based studies reported a prevalence ranging from 13% to 25% in China^{2,4}. This worldwide rise in the prevalence of hyperuricemia and gout may be related to the epidemic diffusion of overweight and obesity⁷, as well as the increased consumption of foods rich in purines⁸, alcohol⁹, and soft drinks sweetened with fructose^{10,11}. As a consequence, the mean serum uric acid levels in United States is increased from 3.4 mg/dL in 1920s¹² to 6.25 mg/dL in 1970s¹³. This implies that perhaps it might be more appropriate to define the reference range of serum uric acid levels according to its physiological role and pathophysiological involvement in human diseases, rather than according to the distribution of its circulating levels in the general population.

Metabolism of Uric Acid

Uric acid is the final product of endogenous and dietary purine metabolism. Uric acid is a weak acid with pKa of 5.75 in the blood and 5.25 in the urine. At a physiological pH of 7.4 in the extracellular compartment the reaction uric acid \leftrightarrow urate H⁺ is shifted to the right; so the majority of uric acid (about 98%) circulates in the blood as ionised urate. Because of the high concentration of sodium in the extracellular compartment, urate is largely present as monosodium urate, with a low solubility limit of about 6 mg/dL (360 μ mol/L)^{14,15}. When urate concentration exceeds this limit the risk of monosodium urate crystal formation and precipitation increases. In urine, which is acidified along the renal tubule, urate is converted into the less soluble uric acid^{14,15}. Diet urate content is generally rather modest (100-200 mg/day), whereas endogenous uric acid mostly derives from de novo synthesis and catabolism of nucleic acids (500-600 mg/day)¹⁴. Endogenous urate is mainly produced in the liver and to a lesser extent in the small intestine. Its production depends on the balance between purine ingestion, intracellular de novo synthesis, recycling, as well as xanthine oxidase function at the end of the purine pathway¹⁶. A relevant cause of overproduction of urate in Western countries is represented by an excess of fructose consumption¹⁰. This sugar is the substrate of the enzyme fructokinase, which generates fructose-1-phosphate by a process in which a molecule of ATP is consumed and a molecule of ADP and organic phosphate are generated. This enzymatic reaction is almost irreversible: ATP is not regenerated while ADP is converted to AMP, which is a substrate for the

generation of uric acid¹⁰. About two-thirds of the uric acid produced daily are eliminated in the kidney, while about a third is eliminated in the gastrointestinal tract due to the activity of intestinal bacteria¹⁴. In human kidney, urate handling involves urate glomerular filtration followed by a complex array of reabsorptive and secretory mechanisms taking place in the proximal tubule¹⁷. Due to its water solubility and low affinity for plasma proteins urate is freely filtered by the glomerulus. At least 90% of the filtered uric acid undergoes active reabsorption in the proximal tubule, and this process is mediated by specific anion transporters, including URAT1^{14,17-19}. This uric acid transporter, localized on the apical side of proximal tubule cells, is an important determinant of the reabsorption of uric acid and is the target of uricosuric drugs such as probenecid, sulfinpyrazone and losartan^{18,19}. The net result of these processes is the elimination in the urine of 7-12% of the filtered load. Chronic treatment with diuretics can reduce urate excretion, probably through an increased reabsorption in the proximal tubule secondary to volume depletion and/or a competition of diuretics with uric acid for secretory mechanisms at the level of the proximal tubule²⁰. This anti-uricosuric effect of diuretics seems to be evident only at doses > 25 mg/day²⁰. Less than 10% of cases of hyperuricemia is due to hyperproduction, while the almost totality of cases is due to reduced excretion^{14,15,21}. Patients with gout due to increased intake of foods rich in purines are generally poor excreters, since they need urate concentrations 120-180 μ mol/L higher than subjects without gout to achieve similar uric acid excretion rates²².

Biological Ambivalence of Uric Acid

Uric acid was initially considered an inert waste product of purine metabolism able to crystallize at high concentrations, causing gouty arthritis and renal stones¹⁴. Recent scientific evidences demonstrated that uric acid exerts different biological effects, depending on its chemical microenvironment, including a protective antioxidant activity as well as a dangerous pro-oxidant action¹⁷. Uric acid alone contributes to about half of the antioxidant capacity of human plasma and its antioxidant properties are comparable to those of ascorbic acid²³. This molecule is capable of preventing the nitrosylation of proteins induced by peroxynitrite, the peroxidation of lipids and proteins, the inactivation of tetrahydrobiopterin, an essential cofactor of nitric oxide synthase, and

the Cu²⁺-mediated LDL oxidation¹⁷. Uric acid also has the ability to prevent degradation of the extracellular superoxide dismutase, a critical enzyme in defending cells from superoxide anion toxicity²⁴. Uric acid can also help to preserve sodium retention and blood pressure²⁵ and, thus, might have played a role in accelerating the development of bipedal locomotion during an evolutionary period in which food was probably scarce and sodium intake low^{26,27}. In addition, uric acid might contribute to the development of insulin resistance and mild obesity²⁸, through its ability to interfere with some actions of insulin by reducing endothelial nitric oxide, as well as to directly act on the adipocyte^{29,30}, thereby favoring survival during a period of famine or stress. Finally, the increase of serum urate concentration might also have led to an improvement in reaction time and mental performance that helped man evolution^{31,32}, or to an amelioration of innate immune function and the ability to ward off infections or tumors^{33,34}. This intriguing hypothesis of a survival advantage deriving from increased circulating levels of uric acid is in contrast with the growing bulk of data suggesting a pathophysiological role of this molecule in human diseases. In addition to the well known link between hyperuricemia and gout, a growing body of evidences suggests that hyperuricemia can possibly lead to cardiovascular, renal and metabolic dysfunction^{15,35}. From a pathophysiological perspective, *in vitro* and cellular studies demonstrated that, depending on the chemical microenvironment, uric acid may exert pro-oxidant or nitric oxide-reducing effects that may explain the association among hyperuricemia, hypertension, metabolic syndrome, and cardiovascular diseases³⁵. Thus, uric acid is a molecule with extremely complex metabolic and biochemical effects that can not be simplistically divided into beneficial or harmful regardless of its microenvironment and, above all, its concentrations in biological fluids¹⁷. Taken together scientific evidences suggest a sort of “collision” between the trajectory of genetic evolution and that of social evolution in the modern era, mainly because of the shifts in dietary habits brought about by increasing prosperity during the last few decades. In today’s societies people consume significantly more meat and fructose, which both generate uric acid. On the other hand, as a consequence of the uricase mutation which occurred in humans and higher primates in mid Miocene³⁶, humans not only have higher uric acid levels than most other mammals, but they al-

so can not regulate these levels effectively^{37,38}. As a consequence, circulating levels of uric acid in the general population are continuously increasing and are nowadays quite higher compared to those observed in primates lacking uricase, who have serum uric acid levels typically in the 3-4 mg/dL range³⁸. In addition, uric acid levels in the primitive Yanomamo of southern Venezuela, whose life conditions were likely similar to those of our prehistoric ancestors, averaged only around 3 mg/dL, suggesting that primitive humans had lower uric acid levels than today²⁷. In modern age subjects who achieve the highest uric acid levels and develop hypertension, insulin resistance, diabetes mellitus, obesity, and cardiovascular diseases³⁷ seem to have lost the evolutionary advantage deriving from uricase gene silencing. Thus, due to the marked changes in diet resulting in a dramatic increase in purine- and fructose-rich foods, increase of serum uric acid levels could represent the expression of a physiological adaptation gone awry in Western societies²⁷.

Uric Acid and Musculoskeletal Damage

Gout is the most common inflammatory arthritis in men, although it is often misdiagnosed or recognized late in its clinical course, especially in elderly subjects, in whom its clinical manifestations may be attributed to osteoarthritis³⁹. The pathophysiology of gout includes, in the presence of hyperuricaemia, the intra-articular deposition of monosodium urate crystals, which is responsible for the onset of acute attacks of inflammatory arthritis, possibly leading to chronic arthropathy¹⁴. Although the formation of monosodium urate crystals in joint fluids mainly depends on the local concentration of urate, it is also influenced by other factors, including articular hydration state, temperature, pH and presence of extracellular matrix proteins such as proteoglycans and collagens^{14,40}. Most often monosodium urate crystals are released from preformed deposits in the joints and are coated by protein or polypeptide molecules including IgG antibodies that facilitate phagocytosis^{14,40}. Protein adsorption is not, however, an indispensable step for cellular activation, as crystals are able to directly interact with monocyte cell membranes as particles^{14,40}. After phagocytosis, crystals activate the NALP3 inflammasoma, a cytoplasmic complex consisting of intracellular immune receptors, thus triggering a typical inflammatory response through release of pro-inflammatory mediators,

such as interleukin 1β and tumour necrosis factor α which in turn, by interacting with specific receptors expressed on synoviocytes, lead to the production of chemokines and the accumulation of neutrophils in the joint⁴¹. The classic gout flare usually develops after years of asymptomatic hyperuricemia, which represents a possible harbinger of clinical gout, being the incidence of gout directly correlated to the degree of hyperuricaemia⁴². Furthermore, monosodium urate deposition was demonstrated to occur in any body fluid with a urate level > 6.8 mg/dL⁴³, and monosodium urate crystals were detected in asymptomatic joints of patients with gout⁴⁴. The presence of monosodium urate crystals in the synovial fluid from asymptomatic individuals with hyperuricemia has been demonstrated by means of polarized light microscopy since early 1980s⁴⁵. Silent deposition of monosodium urate crystals as a result of hyperuricaemia may lead to early destructive skeletal changes: a large percentage of patients with gout and normal radiographs have occult destructive arthropathy detectable by advanced imaging, such as MRI and/or ultrasound⁴⁶. Interestingly, ultrasound evaluation can identify a wide spectrum of sub-clinical morphostructural changes suggestive of gouty arthritis in both intra- and extra-articular structures in asymptomatic individuals. Pineda et al⁴⁷ recently described the typical hyperechoic enhancement of the superficial margin of hyaline cartilage (double contour sign) in 25% of the first metatarsophalangeal joints and in 17% of the femoral cartilage of hyperuricemic asymptomatic individuals (vs 0% in the control group). Patellar and Achilles enthesopathy were also more frequent in hyperuricemic than in normouricemic individuals (12% versus 2.9%; $p = 0.01$ and 15% versus 1.9%, $p = 0.0007$ respectively). The double contour sign has been described in gout only, and reflects the preference of serum urate to crystallize on the surface of cartilage^{48,49}. As confirmation of the presence of monosodium urate in the hyaline cartilage, the double contour sign disappears in patients with gout successfully treated with urate-lowering agents, maintaining serum urate levels below the solubility limit of uric acid (< 6 mg/dL) for at least 7 months⁵⁰. Accordingly, the primary therapeutic goal of urate lowering therapy, i.e. promoting crystal dissolution and preventing crystal formation, is achievable by maintaining serum uric acid levels below the saturation point for monosodium urate⁵¹⁻⁵³. Long term maintenance of serum uric acid levels below

the value of 6 mg/dL results in elimination of gout flares and improvement of tophus status over time⁵⁴. These observations are of great clinical relevance, requiring to carefully reconsider the management of asymptomatic chronic hyperuricemia: although chronically elevated serum urate has not usually been considered to play a pathogenetic role in tissue damage, the ultrasound evidences reported above might warrant the use of urate-lowering agents also in patients with persistent hyperuricemia without clinical signs of gout⁴⁷.

Uric Acid and Traditional Cardiovascular Risk Factors

During the last few decades several epidemiological studies have reported a relation between serum uric acid levels and traditional cardiovascular risk factors, including hypertension, metabolic syndrome and diabetes mellitus, suggesting a possible pathophysiologic link between these conditions⁵⁵. In humans, hyperuricaemia is associated with an increased risk of incident hypertension, which is independent of traditional risk factors and more pronounced in younger individuals with pre-hypertension and in women^{56,57}. On the other hand, treatment with allopurinol of adolescents with hypertension and hyperuricemia was reported to be associated with a significant reduction compared to placebo in systolic (-6.9 ± 4.4 mm Hg vs -2.0 ± 0.4 , $p = 0.007$) and diastolic (-5.1 ± 2.4 mmHg vs -2.4 ± 0.7 , $p = 0.03$) blood pressure⁵⁸. Interestingly, the threshold value of serum uric acid associated with hypertension seems to be as low as 5.0-5.5 mg/dL, clearly below its supersaturation value, thus being probably independent of the formation of monosodium crystals⁵⁶. In adolescents with newly diagnosed, never treated stage 1 essential hypertension and serum uric acid levels > 6 mg/dL, reduction of uric acid levels to values < 5 mg/dL with allopurinol therapy was associated with blood pressure normalization in 86% of patients, as compared with 3% with placebo⁵⁸.

An elevated serum urate concentration is commonly associated with other components of the metabolic syndrome as well⁵⁹. Although the increase in serum urate has often been considered to be secondary, recent evidences suggest that it may play a pathophysiological role in glucose dysmetabolism⁵⁵. Elevated serum urate levels commonly precede insulin resistance, type 2 diabetes mellitus^{60,61}, and obesity⁶², and studies in cell cultures and animal models have suggested a

causative role for urate in the pathogenesis of the metabolic syndrome. A recent metanalysis of 7 eligible articles derived from 8 prospective cohort studies, involving a total of 32,016 participants and 2930 incident cases of type 2 diabetes, provided strong evidence that high levels of serum uric acid are a risk factor for developing type 2 diabetes in middle-aged and older people, independent of other established risk factors, especially metabolic syndrome components⁶³. Interestingly, the presence of only moderately increased serum uric acid levels (> 5.3 mg/dL in women and > 7.0 mg/dL in men) is also associated with a significantly increased risk of developing type 2 diabetes mellitus (hazard ratio: 2.78, 95% CI: 1.35-5.70, $p = 0.0054$)⁶⁴. Pathophysiological mechanisms underlying this association likely include a hyperuricaemia-induced endothelial dysfunction, leading to reduced insulin-stimulated nitric oxide-induced vasodilatation and decreased glucose uptake in skeletal muscle, as well as inflammatory and oxidative changes induced by intracellular urate levels in adipocytes^{35,55}.

Taken together, these findings suggest a pathophysiological relationship between serum uric acid and traditional cardiovascular risk factors which probably starts below the upper threshold value of serum uric acid currently considered as normal in many countries.

Uric Acid and Cardiovascular Diseases

Epidemiological data support a strong association between gout, hyperuricemia and cardiovascular diseases. The analysis of data from 5926 U.S. participants in the National Health and Nutrition Survey (NHANES I) after a mean follow-up of 16.4 years showed a positive relationship between increased levels of uric acid and cardiovascular mortality; for each mg/dL increase in serum uric acid, cardiovascular mortality increased by 9% in men (HR: 1.09, 95% CI: 1.02-1.18) and 26% in women (HR: 1.26, 95% CI: 1.16-1.36)⁶⁵. Interestingly, the increased risk of fatal cardiovascular events associated to elevated serum uric acid levels was especially evident in older individuals at enrollment⁶⁵, suggesting that hyperuricemia must persist for a relatively long time to cause vascular injury, as also observed for traditional cardiovascular risk factors. These findings confirm previous observations in the same population during a survey of shorter duration, demonstrating a mortality from ischemic heart disease 5 times higher among women with

serum uric acid > 7 mg/dL compared to women with a serum uric acid < 4 mg/dL⁶⁶. The relationship between serum uric acid levels and cardiovascular events is also evident for moderately increased levels of uric acid or for values corresponding to the upper limit of the actual normal range, as well as for patients with preexisting cardiovascular disease. In the Preventive Cardiology Information System (PRECIS) Database Cohort Study uric acid levels were significantly higher in patients with a diagnosis of coronary artery disease than in individuals with no history of cardiovascular disease (6.3 ± 1.7 mg/dL versus 5.9 ± 1.6 mg/dL, $p < 0.001$)⁶⁷. After 3 year of follow-up, a 39% increased risk of all-cause mortality (95% CI: 1.28-1.50 $p < 0.001$) was evident for each mg/dL increase in serum uric acid⁶⁷. Similarly, in patients with moderate-to-severe heart failure increased levels of serum uric acid were associated with a worse prognosis, with a linear relationship between uric acid levels and probability of death⁶⁸. The presence of deposits of urate crystals represents an important determinant of increased cardiovascular risk in patients with gout. Data from the screening program conducted in Chang Gung Memorial Hospital in Taiwan from 2000 to 2006 clearly indicate that the risk of fatal cardiovascular events was significantly higher in hyperuricaemic patients with gout (HR: 1.97, 95% CI: 1.08-3.59) compared to subjects without gout (HR: 1.08, 95% CI: 0.78-1.51)⁶⁹. Similarly, in the Multiple Risk Factor Intervention Trial (MRFIT) patients with gout showed a higher risk of coronary events (HR 1.35, 95% CI: 1.06-1.72), mortality from myocardial infarction (HR: 1.35, 95% CI: 0.94-1.93), cardiovascular mortality (HR: 1.21, 95% CI: 0.99-1.49) and all-cause mortality (HR: 1.09, 95% CI: 1.00-1.19) compared to subjects without gout ($p = 0.04$)⁷⁰. More recently, the Health Professionals Follow-up Study confirmed the adverse prognostic impact of chronic deposition of urate, demonstrating an increased risk of total mortality (RR 1.28, 95% CI: 1.15-1.41) and fatal coronary events (RR: 1.38, 95% CI: 1.15-1.66) in individuals with a history of gout⁷¹. These patients also had an increased risk of nonfatal myocardial infarction compared to individuals without gout (RR: 1.59, 95% CI: 1.04-2.41)⁷¹. According to these findings, Stack et al⁷² recently described an independent association of gout and serum uric acid with total and cardiovascular mortality. In particular, mortality risks associated with gout and high serum uric acid levels were

determined for 15,773 participants, aged 20 years or older, in the Third National Health and Nutrition Examination Survey, by linking baseline information collected between 1988 and 1994 with mortality data up to 2006. Compared with subjects without a history of gout, the multivariable hazard ratio for subjects with gout were 1.42 (CI: 1.12-1.82) for total and 1.58 (CI: 1.13-2.19) for cardiovascular mortality. Adjusted hazard ratios for each mg/dL increase in uric acid were 1.16 (CI: 1.10-1.22) for total and cardiovascular mortality and this pattern was consistent across disease categories. In the conjoint analysis, the adjusted hazard ratios for mortality in the highest two uric acid quartiles were 1.64 (CI: 1.08-2.51) and 1.77 (CI: 1.23-2.55), respectively, for subjects with gout, and 1.09 (CI: 0.87-1.37) and 1.37 (CI: 0.11-1.70), respectively, for subjects without gout, compared with those without gout in the lowest quartile. Interestingly, three of the four quartiles of serum uric acid considered in this study were identified by serum uric acid intervals below the threshold of 6 mg/dL (first quartile < 4.3, second 4.3-5.2, third 5.2-6.0 and fourth > 6.0 mg/dL)⁷². These findings are in complete agreement with previous data suggesting that the relation between uric acid and cardiovascular disease is evident not only in the presence of overt hyperuricemia but also with serum uric acid levels considered in the normal to high range (> 5.2 to 5.5 mg/dL)^{55,73,74}. The close relationship between hyperuricemia and cardiovascular events is confirmed by some interesting evidences suggestive of a reduction in the probability of developing cardiovascular events associated with the reduction of serum uric acid levels. A post-hoc analysis of data from the Reduction of Endpoints in type 2 diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated that each 0.5 mg/dL decrease of serum uric acid observed in the first 6 months of treatment, due to the ability of losartan to interfere with renal reabsorption of uric acid thus enhancing renal excretion, was associated with a 5.3% reduction in the risk of cardiovascular events (95% CI: 0.9-9.9, $p = 0.017$)⁷⁵. This finding suggests the possibility that increased levels of uric acid may represent a modifiable cardiovascular risk factor, at least in diabetic patients with renal disease. In line with these findings is the demonstration of a better cardiovascular prognosis in patients with heart failure⁷⁶ or diabetes mellitus⁷⁷ treated with high doses of allopurinol compared to those treated with lower doses of this urate lowering

drug. These results were recently confirmed by a Scottish study that showed a significant reduction in the risk of cardiovascular events (HR: 0.69, 95% CI: 0.50-0.94) and mortality (HR: 0.75, 95% CI: 0.59-0.94) in patients treated with allopurinol 300 mg/day compared to those assuming 100 mg/day of the same drug⁷⁸.

Uric Acid and Brain Health

Increased circulating levels of uric acid have been proposed as an evolutionary advantage for early hominoids due to its potential neurostimulant properties, based on its chemical similarity to caffeine³¹. Several studies described relationships between uric acid levels and IQ testing⁷⁹, achievement-oriented behavior⁸⁰, and school performance⁸¹, although these associations were generally weak. Despite the intriguing hypothesis that uric acid might have neuroprotective properties, elevated serum uric acid levels are also associated with conditions that increase the risk of cognitive dysfunction. Older adults with high normal concentrations of serum uric acid are 2.7 to 5.9 times more likely to score in the bottom quartile for measures of processing speed, verbal memory, and working memory even after adjustment for potential confounding factors such as age, sex, race, education, diabetes, hypertension, smoking, and alcohol intake⁸². Similarly, in patients with chronic kidney disease, defined by a glomerular filtration rate < 60 mL/min/1.73 m², an independent association between circulating levels of uric acid and reduced cognitive performance ($r: -0.297$, $p < 0.0001$) was described⁸³. Furthermore, in the InChianti study, which included a cross-sectional assessment of circulating levels of uric acid and cognitive performance in 1016 community-dwelling elderly subjects, demented patients had higher uric acid levels (5.75 ± 1.90 vs 5.13 ± 1.35 mg/dL, $p < 0.001$) and the prevalence of subjects affected by dementia increased across uric acid tertiles ($p < 0.0001$)⁸⁴. Even after adjustment for possible confounding factors, the highest tertile of serum uric acid was associated with a threefold risk for dementia (OR = 3.32, 95% CI: 1.06 to 10.42), while the intermediate tertile was associated with a higher probability of dementia than the lowest tertile. Interestingly, the relationship between circulating levels of uric acid and dementia was already evident for levels of uric acid essentially below its solubility limit⁸⁴. These findings suggest that the effect of uric acid on cognitive function does not depend on the precipitation of monosodium urate crystals.

In this regard, Schretlen et al⁸⁵ demonstrated that adults with high normal serum uric acid levels are 2.8 times more likely to show greater than average white matter hyperintensity burden, which likely mediates the relationship between serum uric acid and cognitive dysfunction. In another interesting work⁸⁶ by the same group performed in community-dwelling adults aged 20 to 96 years, serum uric acid was significantly associated with greater white matter hyperintensities and poorer working memory, processing speed, fluency, and verbal memory. Associations persisted after controlling for age, sex, race, education, hypertension, diabetes, alcohol abuse, smoking, and body mass. The addition of a term for white matter hyperintensity attenuated these associations, in that uric acid no longer predicted cognitive performance⁸⁶. Taken together these findings indicate that severity of cerebral ischemia might mediate the association between uric acid and cognitive dysfunction. Even more interestingly, circulating levels of serum uric acid in this study population were quite low (4.5 ± 1.4 mg/dL)⁸⁶. Thus, also mild elevations in uric acid appear to contribute to structural and functional brain changes. A growing body of evidence indicates that serum uric acid is also an independent predictor of stroke⁸⁷. Storhaug et al⁸⁸ recently demonstrated in a 12-15 year prospective study on 5700 men and women free of diabetes and cardiovascular diseases, that each 1 SD (1.5 mg/dL) increase in serum uric acid was associated with a 22% increased risk for ischemic stroke and a 13% increased risk for all-cause mortality. Taken together, the above data indicate that serum uric acid might have a detrimental impact on brain vasculature and consequently, on brain structure and function.

Uric Acid and Renal Disease

Experimental studies suggest the possibility that an elevated concentration of uric acid itself can lead to kidney disease without the deposition of uric acid crystals^{89,90}. Animal studies demonstrated that experimental hyperuricaemia obtained through inhibition of uricase can cause de novo kidney disease, as well as accelerate existing renal dysfunctions^{89,90}. The main lesions caused by increased uric acid in the rat are glomerulosclerosis, interstitial fibrosis, and arteriolar disease, conditions similar to those observed in “gouty” nephropathy, except for the absence of intrarenal urate crystals^{89,90}. The mechanism of injury appears to be related to the development of preglomerular arteriolar disease that

impairs the renal autoregulatory response and thereby causes glomerular hypertension⁹¹. In humans a number of cross-sectional studies found an association between urate levels and decreased estimated glomerular filtration rate or microalbuminuria, although the interpretation of these findings is difficult, since chronic kidney disease can elevate urate levels, and hyperuricaemia might cause or aggravate chronic kidney disease. Focusing on incident chronic kidney disease, most studies showed an independent association with serum urate levels. However, the analysis of the progression of chronic kidney disease and its relationship to urate levels gave conflicting results, most studies finding no independent association with hyperuricaemia. This could indicate that urate is a risk factor for the onset of chronic kidney disease more than for its progression⁹². However, a recent review supports the role of urate as a risk factor for chronic kidney disease⁹³. The evidence that the reduction of serum uric acid concentration might favorably affect the clinical course of kidney disease further supports the hypothesis of a detrimental role of uric acid on renal function. Siu et al⁹⁴ demonstrated that 12 months allopurinol treatment decreased systolic blood pressure (from 140 to 127 mmHg) and slowed chronic kidney disease progression. Goicoechea et al⁹⁵ described a favorable effect of allopurinol on estimated glomerular filtration rate decline (defined as a decrease of > 0.2 mL/min/1.73 m²; adjusted HR: 0.53) and a beneficial effect on cardiovascular endpoints (7/57 versus 15/56), but no effect on blood pressure. Momeni et al⁹⁶ described a reduction in proteinuria (from 1.8 to 1.0 versus 1.7 to 1.6 g/24 h) after allopurinol treatment in patients with type 2 diabetes mellitus and diabetic nephropathy. In IgA nephropathy patients Shi et al⁹⁷ described a reduction of the antihypertensive drug doses in 7/9 cases with hypertension during 6 months allopurinol treatment versus 0/9 in the control group. In a posthoc analysis of the Reduction of Endpoints in type 2 diabetes with the Angiotensin II Antagonist Losartan (RENAAL) trial, losartan reduced urate levels by 0.16 mg/dL from 6.7 mg/dL during the first 6 months; adjustment for the urate effect indicated that 1/5 of losartan renoprotective effects could be attributed to this reduction in urate⁹⁸. Taken together, the above findings suggest an influential role of serum uric acid on renal function, which likely starts below its solubility limit, being independent of monosodium urate crystals deposition.

Is it Time To Revise the Upper Threshold for Serum Uric Acid Levels?

In health-related fields, a reference range usually describes the variations of a measurement or value in healthy individuals. In particular, the standard definition of a reference range for a particular measurement is defined as the predicted interval including 95% of values of a reference group, in such a way that in 2.5% of cases a sample value will be smaller than the lower limit of this interval, and in 2.5% of cases it will be larger than the upper limit of this interval, whatever the distribution of these values. By this approach, serum uric acid values between 3.5 and 7.2 mg/dL in adult males and postmenopausal woman and between 2.6 and 6.0 mg/dL in premenopausal women have been identified as normal in many countries. However, epidemiological and experimental data accumulated during the last few decades suggest that this methodological approach to identify reference range could present some weaknesses when applied to serum uric acid levels. Indeed, epidemiological data suggest a progressive worldwide increase of circulating levels of uric acid, which could lead to a “shift to right” (i.e. toward higher values) of normal range. Thus, it seems reasonable to redefine the normal threshold values of uric acid according to its physiological role and its pathophysiological involvement in human diseases. Regarding the target population, healthy subjects are likely to be represented by individuals without clinical evidence of gout. However, a number of evidences suggest that articular damage may occur also without clinical evidence of acute arthritis. In addition, the growing body of evidences presented above suggests that serum uric acid might also exert a detrimental influence on cardiovascular system, brain and kidney and negatively influence glucose metabolism. Interestingly, this influence seems to be evident also for circulating levels of uric acid below its saturation limit, indicating that it is likely independent of precipitation of urate monosodium crystals. Thus, the definition of normal range of serum uric acid in the general population is inevitably influenced by what we consider as “normal”, since the absence of gout flares does not necessarily imply the absence of uric acid related damage. On the other hand, there are also “optimal health ranges” identifying the optimal health impact on people. This might be the case for uric acid, since a threshold value < 6.0 mg/dL (< 360 $\mu\text{mol/L}$)

seems to better identify true “healthy subjects”. Moreover, from an analytical perspective, considering that desirable analytical goals for imprecision and bias should be 4.3% and 4.8%, respectively⁹⁹, for a threshold of serum uric acid concentration of 6.0 mg/dL the imprecision should not exceed 0.26 mg/dL, giving a range of uncertainty between 5.74 and 6.26 mg/dL, i.e. substantially below the solubility limit of uric acid. Therefore, in the light of the new scientific knowledge on hyperuricemia, the recommendable upper threshold value for serum uric acid should reasonably be considered < 6.0 mg/dL. This methodological approach could represent also a strategy to sensitize clinicians towards clinical problems now recognized to be related to uric acid.

Conclusions

Gout is one of the earliest disorders recognised as a clinical entity, which has been associated since its first description to a state of socioeconomic welfare. During the last years, gout has gained renewed interest by clinicians mainly because its continuously increasing prevalence, which is likely to be greater than the epidemiology of “podagra” could suggest. Indeed, radiological evidences demonstrate a wide spectrum of subclinical morphostructural skeletal changes, suggesting that articular damage induced by hyperuricemia can occur in both intra- and extra-articular structures in asymptomatic individuals. These data open a new battlefield in the current debate about the opportunity to maintain serum uric acid levels below the threshold value of 6.0 mg/dL (360 $\mu\text{mol/L}$) also in these subjects as already recommended for patients with overt gouty arthritis⁵¹⁻⁵³. In addition, a growing body of evidences demonstrates that uric acid might play a pathophysiological role in many “cardio-nephro-metabolic” disorders, which seems to be independent of the deposition of monosodium urate crystals, since it is evident also for serum uric acid concentrations below the saturation point for monosodium urate. Taken together, these findings strongly suggest to carefully reconsider the concept of “asymptomaticity” for chronic hyperuricemia and to consequently revise the normal range of serum uric acid levels. A threshold value for serum uric acid < 6.0 mg/dL (< 360 $\mu\text{mol/L}$) should reasonably be considered for all subjects.

Conflict of Interest

The Authors declare that there are no conflicts of interest.

References

- 1) WALLACE KL, RIEDEL AA, JOSEPH-RIDGE N, WORTMANN R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. *J Rheumatol* 2004; 31: 1582-1587.
- 2) RODDY E, DOHERTY M. Epidemiology of gout. *Arthritis Res Ther* 2010; 12: 223.
- 3) KLEMP P, STANSFIELD SA, CASTLE B, ROBERTSON MC. Gout is on the increase in New Zealand. *Ann Rheum Dis* 1997; 56: 22-26.
- 4) MIAO Z, LI C, CHEN Y, ZHAO S, WANG Y, WANG Z, CHEN X, XU F, WANG F, SUN R, HU J, SONG W, YAN S, WANG CY. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. *J Rheumatol* 2008; 35: 1859-1864.
- 5) TRIFIRÒ G, MORABITO P, CAVAGNA L, FERRAJOLO C, PECCHIOLO S, SIMONETTI M, BIANCHINI E, MEDEA G, CRICELLI C, CAPUTI AP, MAZZAGLIA G. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. *Ann Rheum Dis* 2013; 72: 694-700.
- 6) ZHU Y, PANDYA BJ, CHOI HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011; 63: 3136-3141.
- 7) CHOI HK, ATKINSON K, KARLSON EW, CURHAN G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. *Arch Intern Med* 2005; 165: 742-748.
- 8) CHOI HK, ATKINSON K, KARLSON EW, WILLETT W, CURHAN G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. *N Engl J Med* 2004; 350: 1093-1103.
- 9) CHOI HK, ATKINSON K, KARLSON EW, WILLETT W, CURHAN G. Alcohol intake and risk of incident gout in men: a prospective study. *Lancet* 2004; 363: 1277-1281.
- 10) CHOI HK, CURHAN G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. *BMJ* 2008; 336: 309-312.
- 11) CHOI JW, FORD ES, GAO X, CHOI HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. *Arthritis Rheum* 2008; 59: 109-116.
- 12) FISHBERG AM. The interpretation of blood uric acid in hypertension. *Arch Intern Med (Chic)* 1924; 34: 503-507.
- 13) GLYNN RJ, CAMPION EW, SILBERT JE. Trends in serum uric acid levels 1961-1980. *Arthritis Rheum* 1983; 26: 87-93.
- 14) RICHETTE P, BARDIN T. Gout. *Lancet* 2010; 375: 318-328.
- 15) GRASSI D, FERRI L, DESIDERI G, DI GIOSIA P, CHELI P, DEL PINTO R, PROPERZI G, FERRI C. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. *Curr Pharm Des* 2013; 19: 2432-2438.
- 16) TERKELTAUB R, BUSHINSKY DA, BECKER MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. *Arthritis Res Ther* 2006; 8(Suppl 1): S4.
- 17) SO A, THORENS B. Uric acid transport and disease. *J Clin Invest* 2010; 120: 1791-1799.
- 18) ENOMOTO A, KIMURA H, CHAIROUNGDU A, SHIGETA Y, JUTABHA P, CHA SH, HOSOYAMADA M, TAKEDA M, SEKINE T, IGARASHI T, MATSUI H, KIKUCHI Y, ODA T, ICHIDA K, HOSOYA T, SHIMOKATA K, NIWA T, KANAI Y, ENDOU H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. *Nature* 2002; 417: 447-452.
- 19) HAMADA T, ICHIDA K, HOSOYAMADA M, MIZUTA E, YANAGIHARA K, SONOYAMA K, SUGIHARA S, IGAWA O, HOSOYA T, OHTAHARA A, SHIGAMASA C, YAMAMOTO Y, NINOMIYA H, HISATOME I. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. *Am J Hypertens* 2008; 21: 1157-1162.
- 20) PASCUAL E, PERDIGUERO M. Gout, diuretics and the kidney. *Ann Rheum Dis* 2006; 65: 981-982.
- 21) NEOGI T. Clinical practice. Gout. *N Engl J Med* 2011; 364: 443-452.
- 22) SIMKIN PA. Urate excretion in normal and gouty men. *Adv Exp Med Biol* 1977; 76B: 41-45.
- 23) PROCTOR P. Similar functions of uric acid and ascorbate in man? *Nature* 1970; 228: 868.
- 24) HINK HU, SANTANAM N, DIKALOV S, MCCANN L, NGUYEN AD, PARTHASARATHY S, HARRISON DG, FUKAI T. Peroxidase properties of the extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. *Arterioscler Thromb Vasc Biol* 2002; 22: 1402-1408.
- 25) WATANABE S, KANG DH, FENG L, NAKAGAWA T, KANELIS J, LAN H, MAZZALI M, JOHNSON RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. *Hypertension* 2002; 40: 355-360.
- 26) EATON SB, KONNER M. Paleolithic nutrition. A consideration of its nature and current implications. *N Engl J Med* 1985; 312: 283-289.
- 27) JOHNSON RJ, SAUTIN YY, OLIVER WJ, RONCAL C, MU W, GABRIELA SANCHEZ-LOZADA L, RODRIGUEZ-ITURBE B, NAKAGAWA T, BENNER SA. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? *J Comp Physiol B* 2009; 179: 67-76.
- 28) NAKAGAWA T, TUTTLE KR, SHORT RA, JOHNSON RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. *Nat Clin Pract Nephrol* 2005; 1: 80-86.
- 29) KHOSLA UM, ZHARIKOV S, FINCH JL, NAKAGAWA T, RONCAL C, MU W, KROTOVA K, BLOCK ER, PRABHAKAR S, JOHNSON RJ. Hyperuricemia induces endothelial dysfunction. *Kidney Int* 2005; 67: 1739-1742.

- 30) SAUTIN YY, NAKAGAWA T, ZHARIKOV S, JOHNSON RJ. Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. *Am J Physiol Cell Physiol* 2007; 293: C584-C596.
- 31) OROWAN E. The origin of man. *Nature* 1955; 175: 683-684.
- 32) INOUE E, PARK KS, ASAKA A. Blood uric acid level and IQ: a study in twin families. *Acta Genet Med Gemellol (Roma)* 1984; 33: 237-242.
- 33) SHI Y, EVANS JE, ROCK KL. Molecular identification of a danger signal that alerts the immune system to dying cells. *Nature* 2003; 425: 516-521.
- 34) HU DE, MOORE AM, THOMSEN LL, BRINDLE KM. Uric acid promotes tumor immune rejection. *Cancer Res* 2004; 64: 5059-5062.
- 35) KANELIS J, KANG DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. *Semin Nephrol* 2005; 25: 39-42.
- 36) WU XW, MUZYNY DM, LEE CC, CASKEY CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. *J Mol Evol* 1992; 34: 78-84.
- 37) JOHNSON RJ, RIDEOUT BA. Uric acid and diet--insights into the epidemic of cardiovascular disease. *N Engl J Med* 2004; 350: 1071-1073.
- 38) JOHNSON RJ, TITTE S, CADE JR, RIDEOUT BA, OLIVER WJ. Uric acid, evolution and primitive cultures. *Semin Nephrol* 2005; 25: 3-8.
- 39) NING TC, KEENAN RT. Gout in the elderly. *Clinical Geriatrics* 2011; 19: 20-25.
- 40) MCLEAN L. The pathogenesis of gout. In: Hochberg M, ed. *Rheumatology*: Edinburgh: Mosby, 2003; pp. 1903-1918.
- 41) PÉTRILLI V, MARTINON F. The inflammasome, autoinflammatory diseases, and gout. *Joint Bone Spine* 2007; 74: 571-576.
- 42) CAMPION EW, GLYNN RJ, DELABRY LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. *Am J Med* 1987; 82: 421-426.
- 43) BECKER MA, LEVINSON D. Clinical gout and pathogenesis of hyperuricemia. In: Koopman WJ, ed. *Arthritis and allied conditions*, 13th edn. Baltimore: Williams & Wilkins, 1996; pp. 2041-2072.
- 44) BOMALASKI JS, LLUBERAS G, SCHUMACHER HR JR. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. *Arthritis Rheum* 1986; 29: 1480-1484.
- 45) ROUAULT T, CALDWELL DS, HOLMES EW. Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls. *Arthritis Rheum* 1982; 25: 209-212.
- 46) CARTER JD, KEDAR RP, ANDERSON SR, OSORIO AH, ALBRITTON NL, GNANASHANMUGAM S, VALERIANO J, VASEY FB, RICCA LR. An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs. *Rheumatology* 2009; 48: 1442-1446.
- 47) PINEDA C, AMEZCUA-GUERRA LM, SOLANO C, RODRIGUEZ-HENRÍQUEZ P, HERNÁNDEZ-DÍAZ C, VARGAS A, HOFMANN F, GUTIÉRREZ M. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. *Arthritis Res Ther* 2011; 13: R4.
- 48) WRIGHT SA, FILIPPUCCI E, MCVEIGH C, GREY A, MCCARRON M, GRASSI W, WRIGHT GD, TAGGART AJ. High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. *Ann Rheum Dis* 2007; 66: 859-864.
- 49) THIELE RG, SCHLESINGER N. Diagnosis of gout by ultrasound. *Rheumatology (Oxford)* 2007; 46: 1116-1121.
- 50) THIELE RG, SCHLESINGER N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normuricemia is achieved. *Rheumatol Int* 2010; 30: 495-503.
- 51) KHANNA D, FITZGERALD JD, KHANNA PP, BAE S, SINGH MK, NEOGI T, PILLINGER MH, MERILL J, LEE S, PRAKASH S, KALDAS M, GOGIA M, PEREZ-RUIZ F, TAYLOR W, LIOTÉ F, CHOI H, SINGH JA, DALBETH N, KAPLAN S, NIYYAR V, JONES D, YAROWS SA, ROESSLER B, KERR G, KING C, LEVY G, FURST DE, EDWARDS NL, MANDELL B, SCHUMACHER HR, ROBBINS M, WENGER N, TERKELTAUB R; AMERICAN COLLEGE OF RHEUMATOLOGY. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res* 2012; 64: 1431-1446.
- 52) ZHANG W, DOHERTY M, BARDIN T, PASCUAL E, BARSKOVA V, CONAGHAN P, GERSTER J, JACOBS J, LEEB B, LIOTÉ F, MCCARTHY G, NETTER P, NUKI G, PEREZ-RUIZ F, PIGNONE A, PIMENTÃO J, PUNZI L, RODDY E, UHLIG T, ZIMMERMANN-GÖRSKA I; EULAR STANDING COMMITTEE FOR INTERNATIONAL CLINICAL STUDIES INCLUDING THERAPEUTICS. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ES-CISIT). *Ann Rheum Dis* 2006; 65: 1312-1324.
- 53) MANARA M, BORTOLUZZI A, FAVERO M, PREVETE I, SCIRÈ CA, BIANCHI G, BORCHI C, CIMMINO MA, D'AVOLA GM, DESIDERI G, DI GIACINTO G, GOVONI M, GRASSI W, LOMBARDI A, MARANGELLA M, MATUCCI CERINIC M, MEDEA G, RAMONDA R, SPADARO A, PUNZI L, MINISOLA G. Italian Society of Rheumatology recommendations for the management of gout. *Reumatismo* 2013; 65: 4-21.
- 54) BECKER MA, SCHUMACHER HR, MACDONALD PA, LLOYD E, LADEMACHER C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. *J Rheumatol* 2009; 36: 1273-1282.
- 55) FEIG DI, KANG DH, JOHNSON RJ. Uric acid and cardiovascular risk. *N Engl J Med* 2008; 359: 1811-1821.
- 56) GRAYSON PC, KIM SY, LAVALLEY M, CHOI HK. Hyperuricemia and incident hypertension: a systemic review and meta-analysis. *Arthritis Care Res* 2011; 63: 102-110.

- 57) FEIG DI, JOHNSON RJ. Hyperuricemia in childhood primary hypertension. *Hypertension* 2003; 42: 247-252.
- 58) FEIG DI, SOLETSKY B, JOHNSON RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. *JAMA* 2008; 300: 924-932.
- 59) TSOULI SG, LIBEROPOULOS EN, MIKHAILIDIS DP, ATHYROS VG, ELISAF MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? *Metabolism* 2006; 55: 1293-1301.
- 60) KODAMA S, SAITO K, YACHI Y, ASUMI M, SUGAWARA A, TOTSUKA K, SAITO A, SONE H. Association between serum uric acid and development of type 2 diabetes. *Diabetes Care* 2009; 32: 1737-1742.
- 61) DEHGHAN A, VAN HOEK M, SUBBRANDS EJ, HOFMAN A, WITTEMAN JC. High serum uric acid as a novel risk factor for type 2 diabetes. *Diabetes Care* 2008; 31: 361-362.
- 62) MASUO K, KAWAGUCHI H, MIKAMI H, OGIHARA T, TUCK ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. *Hypertension* 2003; 42: 474-480.
- 63) LV Q, MENG XF, HE FF, CHEN S, SU H, XIONG J, GAO P, TIAN XJ, LIU JS, ZHU ZH, HUANG K, ZHANG C. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. *PLoS One* 2013; 8: e56864.
- 64) VIAZZI F, LEONCINI G, VERCELLI M, DEFERRARI G, PONTREMOLI R. Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. *Diabetes Care* 2011; 34: 126-128.
- 65) FANG J, ALDERMAN MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. *National Health and Nutrition Examination Survey. JAMA* 2000; 283: 2404-2410.
- 66) FREEDMAN DS, WILLIAMSON DF, GUNTER EW, BYERS T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. *Am J Epidemiol* 1995; 141: 637-644.
- 67) IOACHIMESCU AG, BRENNAN DM, HOAR BM, HAZEN SL, HOOGWERF BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. *Arthritis Rheum* 2008; 58: 623-630.
- 68) ANKER SD, DOEHNER W, RAUCHHAUS M, SHARMA R, FRANCIS D, KNOSALLA C, DAVOS CH, CICOIRA M, SHAMIM W, KEMP M, SEGAL R, OSTERZIEL KJ, LEYVA F, HETZER R, PONIKOWSKI P, COATS AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. *Circulation* 2003; 107: 1991-1997.
- 69) KUO CF, SEE LC, LUO SF, KO YS, LIN YS, HWANG JS, LIN CM, CHEN HW, YU KH. Gout: an independent risk factor for all-cause and cardiovascular mortality. *Rheumatology (Oxford)* 2010; 49: 141-146.
- 70) KRISHNAN E, SVENDSEN K, NEATON JD, GRANDITS G, KULLER LH; MRFIT RESEARCH GROUP. Long-term cardiovascular mortality among middle-aged men with gout. *Arch Intern Med* 2008; 168: 1104-1110.
- 71) CHOI HK, CURHAN G. Independent impact of gout on mortality and risk for coronary heart disease. *Circulation* 2007; 116: 894-900.
- 72) STACK AG, HANLEY A, CASSERLY LF, CRONIN CJ, ABDALLA AA, KIERNAN TJ, MURTHY BV, HEGARTY A, HANNIGAN A, NGUYEN HT. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. *QJM* 2013; 106: 647-658.
- 73) NISKANEN LK, LAAKSONEN DE, NYSSÖNEN K, ALFTHAN G, LAKKA HM, LAKKA TA, SALONEN JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. *Arch Intern Med* 2004; 164: 1546-1551.
- 74) VERDECCHIA P, SCHILLACI G, REBOLDI G, SANTEUSANIO F, PORCELLATI C, BRUNETTI P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. *Hypertension*. 2000; 36: 1072-1078.
- 75) SMINK PA, BAKKER SJ, LAVERMAN GD, BERL T, COOPER ME, DE ZEEUW D, LAMBERS HEERSPIJK HJ. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. *J Hypertens* 2012; 30: 1022-1028.
- 76) STRUTHERS AD, DONNAN PT, LINDSAY P, McNAUGHTON D, BROOMHALL J, MACDONALD TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. *Heart* 2002; 87: 229-234.
- 77) ZOPPINI G, TARGHER G, NEGRI C, STOICO V, PERRONE F, MUGGEO M, BONORA E. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. *Diabetes Care* 2009; 32: 1716-1720.
- 78) WEI L, MACKENZIE IS, CHEN Y, STRUTHERS AD, MACDONALD TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. *Br J Clin Pharmacol* 2011; 71: 600-607.
- 79) STETTEN D JR, HEARON JZ. Intellectual level measured by army classification battery and serum uric acid concentration. *Science* 1959; 129: 1737.
- 80) BROOKS GW, MUELLER E. Serum urate concentrations among university professors: relation to drive, achievement, and leadership. *JAMA* 1966; 195: 415-418.
- 81) BLOCH S, BRACKENRIDGE CJ. Psychological, performance and biochemical factors in medical students under examination stress. *J Psychosom Res* 1972; 16: 25-33.
- 82) SCHRETLEN DJ, INSCORE AB, JINNAH HA, RAO V, GORDON B, PEARLSON GD. Serum uric acid and cogni-

- tive function in community-dwelling older adults. *Neuropsychology* 2007; 21: 136-140.
- 83) AFSAR B, ELSURER R, COVIC A, JOHNSON RJ, KANBAY M. Relationship between uric acid and subtle cognitive dysfunction in chronic kidney disease. *Am J Nephrol* 2011; 34: 49-54.
- 84) RUGGIERO C, CHERUBINI A, LAURETANI F, BANDINELLI S, MAGGIO M, DI IORIO A, ZULIANI G, DRAGONAS C, SENIN U, FERRUCCI L. Uric acid and dementia in community-dwelling older persons. *Dement Geriatr Cogn Disord* 2009; 27: 382-389.
- 85) SCHRETLEN DJ, INSCORE AB, VANNORS DALL TD, KRAUT M, PEARLSON GD, GORDON B, JINNAH HA. Serum uric acid and brain ischemia in normal elderly adults. *Neurology* 2007; 69: 1418-1423.
- 86) VANNORS DALL TD, JINNAH HA, GORDON B, KRAUT M, SCHRETLEN DJ. Cerebral ischemia mediates the effect of serum uric acid on cognitive function. *Stroke* 2008; 39: 3418-3420.
- 87) KIM SY, GUEVARA JP, KIM KM, CHOI HK, HEITJAN DF, ALBERT DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. *Arthritis Rheum* 2009; 61: 885-892.
- 88) STORHAUG HM, NORVIK JV, TOFT II, ERIKSEN BO, LØCHEN ML, ZYKOVA S, SOLBU M, WHITE S, CHADBAN S, JENSSSEN T. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study. *BMC Cardiovasc Disord* 2013; 13: 115.
- 89) MAZZALI M, HUGHES J, KIM YG, JEFFERSON JA, KANG DH, GORDON KL, LAN HY, KIVLIGHN S, JOHNSON RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension* 2001; 38: 1101-1106.
- 90) KANG DH, NAKAGAWA T, FENG L, WATANABE S, HAN L, MAZZALI M, TRUONG L, HARRIS R, JOHNSON RJ. A role for uric acid in the progression of renal disease. *J Am Soc Nephrol* 2002; 13: 2888-2897.
- 91) SÁNCHEZ-LOZADA LG, TAPIA E, SANTAMARÍA J, AVILA-CASADO C, SOTO V, NEPOMUCENO T, RODRÍGUEZ-ITURBE B, JOHNSON RJ, HERRERA-ACOSTA J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. *Kidney Int* 2005; 67: 237-247.
- 92) GUSTAFSSON D, UNWIN R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. *BMC Nephrology* 2013; 14: 164.
- 93) JOHNSON RJ, NAKAGAWA T, JALAL D, SÁNCHEZ-LOZADA LG, KANG DH, RITZ E. Uric acid and chronic kidney disease: which is chasing which? *Nephrol Dial Transplant* 2013; 28: 2221-2228.
- 94) SIU YP, LEUNG KT, TONG MK, KWAN TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. *Am J Kidney Dis* 2006; 47: 51-59.
- 95) GOICOECHEA M, DE VINUESA SG, VERDALLES U, RUIZ-CARO C, AMPUERO J, RINCÓN A, ARROYO D, LUÑO J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol* 2010; 5: 1388-1393.
- 96) MOMENI A, SHAHIDI S, SEIRAFIAN S, TAHERI S, KHEIRI S. Effect of allopurinol in decreasing proteinuria in Type 2 diabetic patients. *Iran J Kidney Dis* 2010; 4: 128-132.
- 97) SHI Y, CHEN W, JALAL D, LI Z, CHEN W, MAO H, YANG Q, JOHNSON RJ, YU X. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. *Kidney Blood Press Res* 2012; 35: 153-160.
- 98) MIAO Y, OTTENBROS SA, LAVERMAN GD, BRENNER BM, COOPER ME, PARVING HH, GROBBEE DE, SHAHINFAR S, DE ZEEUW D, LAMBERS HEERSPINK HJ. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. *Hypertension* 2011; 58: 2-7.
- 99) RICÓS C, ALVAREZ V, CAVA F, GARCÍA-LARIO JV, HERNÁNDEZ A, JIMÉNEZ CV, MINCHINELA J, PERICH C, SIMÓN M. Current databases on biological variation: pros, cons and progress. *Scand J Clin Lab Invest* 1999; 59: 491-500.